Novartis' Rhapsido Hits Phase 3 Goals for MS | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the dynamic landscape of the industry, highlighting significant scientific breakthroughs, strategic partnerships, and regulatory updates that are reshaping healthcare as we know it.

Novartis recently announced a major milestone with its BTK inhibitor, Rhapsido, which met its Phase 3 clinical trial goals for treating relapsing multiple sclero...